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Abstract 
Background: Psoriasis patients exhibit an increased risk of atherothrombotic events, including myocardial infarc-
tion and stroke. Clinical evidence suggests that psoriasis patients with early onset and more severe disease have 
the highest risk for these co-morbidities, perhaps due to the extent of body surface involvement, subsequent levels 
of systemic inflammation, or chronicity of disease. We sought to determine whether acute or chronic skin-specific 
inflammation was sufficient to promote thrombosis.
Methods: We used two experimental mouse models of skin-specific inflammation generated in either an acute 
(topical Aldara application onto wild-type C57Bl/6 mice for 5 days) or chronic (a genetically engineered K5-IL-17C 
mouse model of psoriasiform skin inflammation) manner. Arterial thrombosis was induced using carotid artery pho-
tochemical injury (Rose Bengal-green light laser) and carotid artery diameters were measured post-clot formation. 
We also examined measures of clot formation including prothrombin (PT) and activated partial thromboplastin time 
(aPTT). Skin inflammation was examined histologically and we profiled plasma-derived lipids. The number of skin-
draining lymph-node (SDLN) and splenic derived CD11b+Ly6Chigh pro-inflammatory monocytes and CD11b+Ly6G+ 
neutrophils was quantified using multi-color flow cytometry.
Results: Mice treated with topical Aldara for 5 days had similar carotid artery thrombotic occlusion times to mice 
treated with vehicle cream (32.2 ± 3.0 vs. 31.4 ± 2.5 min, p = 0.97); in contrast, K5-IL-17C mice had accelerated occlu-
sion times compared to littermate controls (15.7 ± 2.1 vs. 26.5 ± 3.5 min, p < 0.01) while carotid artery diameters 
were similar between all mice. Acanthosis, a surrogate measure of inflammation, was increased in both Aldara-treated 
and K5-IL-17C mice compared to their respective controls. Monocytosis, defined as elevated SDLN and/or splenic 
CD11b+Ly6Chigh cells, was significantly increased in both Aldara-treated (SDLN: 3.8-fold, p = 0.02; spleen: 2.0-fold, 
p < 0.01) and K5-IL-17C (SDLN: 3.4-fold, p = 0.02; spleen: 3.5-fold, p < 0.01) animals compared to controls while neu-
trophilia, defined as elevated SDLN and/or splenic CD11b+Ly6G+ cells, was significantly increased in only the chronic 
K5-IL-17C model (SDLN: 11.6-fold, p = 0.02; spleen: 11.3-fold, p < 0.01). Plasma-derived lipid levels, PT and aPTT times 
showed no difference between the Aldara-treated mice or the K5-IL-17C mice and their respective controls.
Conclusions: Chronic, but not acute, skin-specific inflammation was associated with faster arterial thrombotic 
occlusion. Increased numbers of splenic and SDLN monocytes were observed in both acute and chronic skin-specific 
inflammation, however, increased splenic and SDLN neutrophils were observed only in the chronic skin-specific 
inflammation model. Understanding the cellular response to skin-specific inflammation may provide insights into the 
cellular participants mediating the pathophysiology of major adverse cardiovascular events associated with psoriasis.
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Background
Psoriasis vulgaris is a chronic inflammatory skin disease 
that affects  ~2  % of Americans and is characterized by 
red, scaly, well-demarcated plaques containing activated 
immune cells [1]. The disease is associated with numer-
ous co-morbidities including psoriatic arthritis [2], dia-
betes [3], kidney disease [4], and metabolic syndrome [5]. 
Psoriasis patients also experience increased depression 
and societal stigmatization [6]. Importantly, individuals 
with psoriasis have an increased risk of developing and 
dying of cardiovascular disease (CVD) [7, 8]. Likewise, 
patients with severe psoriasis have an increased risk of 
experiencing an adverse cardiovascular event, such as 
stroke or myocardial infarction (MI) [9], and this occurs 
independent of other CVD risk factors including age, 
gender, smoking, diabetes, hypertension, and hyperlipi-
demia [8]. Causality between psoriasis and CVD is chal-
lenging to explore; however, many commonalities exist 
at the cellular and molecular levels between the two 
diseases [10, 11] and treating psoriasis patients with sys-
temic anti-inflammatory drugs may improve associated 
CVD outcomes [12].
Recently, we generated and reported a murine model of 
psoriasis driven by keratinocyte-specific overexpression 
of Interleukin (IL)-17C, the K5-IL-17C mouse [13]. IL-
17C is an IL-17 family member believed to signal through 
the receptors IL-17RE/RA [14]. IL-17A and IL-17F are 
the most highly characterized IL-17 cytokines in the con-
text of psoriasis pathogenesis [15]; however, IL-17C is 
the most abundant IL-17 isoform expressed in lesional 
human psoriasis skin [16], and is rapidly responsive to 
efficacious biologics, implicating a potential pathogenic 
role in disease [15]. To explore this possibility, K5-IL-
17C mice were genetically engineered to model increased 
epidermal IL-17C expression [13], and develop a spon-
taneous skin phenotype similar to human psoriasis that 
includes the development of disease after birth (i.e. the 
phenotype begins to appear at ~6–8 weeks of age), well-
demarcated skin lesions with clear gross demarcation 
between uninvolved and involved skin, an IL-12/23-Th1/
Th17 immune cell phenotype, and improvement of skin 
pathology upon treatment with TNF-α antagonists [13].
This model system offers a unique opportunity to con-
firm a pro-thrombotic phenotype resulting from chronic 
skin-specific inflammation and demonstrate the impor-
tance of exposure time to inflammation, or chronicity, 
to this cardiovascular outcome. Our prior work demon-
strated keratinocyte-containment of the transgene using 
genetic-reporter approaches [17]; thus, we hypothesize 
that K5-IL-17C mice will develop enhanced thrombosis 
as a direct result of chronic skin-specific inflammation 
in the presence of elevated circulating proinflamma-
tory monocytes, similar to that observed in the KC-Tie2 
mouse model [17]. Of translational importance, recent 
work done by our group [18] and others (Dr. Nehal 
Mehta, NHLBI, personal communication) have identi-
fied circulating pro-inflammatory monocytes in psoria-
sis patients that resemble the increased CD11b+Ly6Chigh 
cells observed in the KC-Tie2 model, and which we 
hypothesize will also be elevated in K5-IL-17C mice, pro-
viding a potential link between chronic skin inflamma-
tion and the CVD co-morbidities.
Gene-specific contributions to skin inflammation have 
recently been investigated pre-clinically using acute 
(5  days) topical application of Aldara (5  % imiquimod; 
a TLR7/8 agonist) [19]. Controversy over whether this 
model is appropriate for studying psoriasis pathogenesis 
has ensued, in part due to the timing of this elicitation, 
as well as the lack of chronicity associated with human 
psoriasis. However, this treatment does model some 
early events in psoriasiform plaque formation, such as 
increased acanthosis. Both the K5-IL-17C (chronic) 
model and the Aldara (acute) model result in increased 
infiltrating dermal T cells, dendritic cells, and mac-
rophages into lesional tissue [13, 19]. Moreover, similar 
patterns of elevated pro-inflammatory gene transcripts 
are observed in lesional skin of both models, including 
IL-12/23, TNF-α, IL-17A, and IL-17C [13, 19, 20]. These 
unique experimental models provide the opportunity to 
compare acute vs. chronic skin-specific inflammation 




K5-IL-17C mice on a C57Bl/6 background were bred 
and genotyped as previously described [13] in the Case 
Western Reserve University (CWRU) animal vivarium. 
Littermates carrying a single non-expressing transgene 
(either K5tTA or TetosIL-17C) or no transgenes [herein 
called C57Bl/6, wildtype (WT)] were used as littermate 
controls. For Aldara experiments, C57Bl/6 mice were 
purchased (Jackson Laboratories, Bar Harbor, ME, USA) 
and allowed to acclimatize to the CWRU animal vivar-
ium for at least 14  days before beginning topical appli-
cation of either Aldara or control cream. All mice used 
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in the experiments were of similar age (10–16  weeks of 
age), and both male and female mice were used for all 
experimental outcomes. Average body weights (in grams) 
were as follows: WT  +  vehicle (21.8  ±  0.24, n  =  21), 
WT +  Aldara (19.8 ±  0.22, n =  25), WT (22.1 ±  1.01, 
n = 18) and K5-IL-17C (17.3 ± 0.40, n = 14).
For Aldara experiments, mice were shaved 1  day 
prior to application of either Aldara or control cream (a 
petroleum-based cream), which was spread on the dor-
sal surface of the mouse (5  % Aldara, 3  M Pharmaceu-
ticals; 62.5  mg) daily for a period of 5  days. As needed, 
mice were provided with IP saline to supplement fluid 
loss associated with Aldara treatment, a well-known side-
effect [21]. On day 6, mice underwent the thrombosis 
protocol outlined below.
Post-hoc statistical analyses examining potential sex-
differences were completed. No differences between 
sexes were observed for any of our reported outcomes 
thus male and female animals were grouped together for 
all experimental analyses.
All animal protocols were approved by the CWRU 
Institutional Animal Care and Use Committee and con-
formed to the American Association for Accreditation of 
Laboratory Animal Care guidelines.
Rose Bengal occlusive thrombosis
The Rose Bengal thrombosis vascular occlusion assay 
was completed as previously described [17]. Briefly, male 
and female K5-IL-17C mice [n = 14; male (5), female (9)] 
or littermate controls [n = 21; male (10), female (11)] or 
C57Bl/6 WT mice treated with either Aldara [n  =  25; 
male (11), female (14)] or control cream [n =  21; male 
(10), female (11)] were deeply anesthetized and had their 
right common carotid artery exposed and monitored 
by a Doppler flow probe. Animals received a tail-vein 
injection of Rose Bengal (50  mg/kg) followed by laser 
illumination of the carotid artery (540  nm) to initiate 
thrombosis as described previously [22]. Blood flow was 
monitored until occlusion occurred, defined as cessation 
of blood flow for 10 min.
Carotid artery collection post thrombosis
The right common carotid artery of the mouse under-
going the thrombosis procedure was isolated from sur-
rounding tissues prior to thrombosis induction and two 
silk sutures were placed under the proximal and distal 
ends of the carotid artery, respectively. A loose knot that 
did not disturb blood flow was made on each end of the 
carotid artery. After blood flow was blocked for 10 min 
continuously as a result of thrombosis induction, the 
two loose knots were tightened to prevent the leakage 
of the thrombus clot formed and the artery segment was 
removed.
Tissue processing and measurement of carotid diameters
The closed-end-carotid artery with thrombus was then 
fixed in 4  % formaldehyde (Fisher Scientific, Waltham, 
MA, USA), and subjected to standard histological paraf-
fin embedding and sectioning. Thin (5 μm) sections with 
thrombi were collected sequentially and stained with 
hematoxylin and eosin (H&E). Images were acquired 
using a Zeiss camera (AxioCam MRc5) linked to a micro-
scope (LEICA DM2000). The diameter of the artery 
(micrometers) was determined by collecting 4 independ-
ent measurements distributed evenly across the cross-
section of the measured artery and averaged for each 
animal.
Tissue harvesting and flow cytometry
Following thrombosis, skin was harvested and processed 
as described previously for histology and immunohis-
tochemistry [13, 23]. Skin draining axial and inguinal 
lymph nodes were isolated from a subset of K5-IL-17C 
transgenic mice and littermate controls (n  =  6 and 
n  =  15; respectively) and Aldara- or control cream-
treated C57Bl/6 WT mice (n = 12 and n = 11; respec-
tively) and were then pooled. Spleens were isolated from 
a subset of K5-IL-17C transgenic mice and littermate 
controls and Aldara- or control cream-treated C57Bl/6 
WT mice (n = 4–9). These tissues were homogenized in 
serum-free media containing 50 μg/ml DNase I (Sigma, 
St. Louis, MO) and 2  mg/ml collagenase D (Roche, 
Basil). Isolated cells were then pelleted, re-suspended, 
and filtered 2×  through a 70  μm filter in wash buffer 
containing 5 % FBS. The cells were immediately stained 
for the cell surface markers Ly6C (Alexa Fluor 700; eBi-
osciences, San Diego, CA, USA), Ly6G (APC; Abcam, 
Cambridge, MA, USA), and CD11b (eFlour450; BD, 
Franklin Lakes, NJ, USA). Flow cytometry data collec-
tion was performed using a BD FACS-Aria instrument 
and analyzed using FlowJo software (Tree Star, Ashland, 
OR, USA).
See Additional file 1: Figure S1 for gating strategy. For 
monocyte cell gating, monocytes were first selected on 
an FSC-A vs. SSC-A plot (S1, panel A). The monocytes 
were then analyzed for live/dead cell populations using 
the exclusion dye 7-AAD (S1, panel B). From the live 
monocyte gate, singlet cells were selected and the dou-
blet events were excluded (S1, panel C). Live singlet cells 
were then selected for CD11b+Ly6Gneg cells (bottom gate 
in S1, panel D). From this population, Ly6C was plotted 
versus SSC-A, and cells that are high on Ly6C and low 
on SSC-A were considered CD11b+Ly6Chigh, exclud-
ing CD11b+Ly6Clow cells and eosinophils (red box in S1, 
panel E). CD11b+Ly6G+ neutrophils were gated as shown 
in panels S1 A, B, and C and were defined as the popula-
tion in the top gate with dashed black line in S1, panel D.
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Clotting assays
Activated partial thromboplastin time
The activated partial thromboplastin time (aPTT) was 
performed as described previously [24] with modifica-
tion. Briefly, 50  μl of aPTT reagent (aPTT-SA, Helena 
Laboratories, Beaumont, Texas, USA) was incubated with 
50  μl sodium citrate-anticoagulated plasma at 37  °C for 
5 min. Fifty microliters of 30 mM calcium chloride was 
then added and the time to clot formation was recorded. 
All samples were tested in duplicate.
Prothrombin time
The prothrombin time (PT) was performed as described 
previously [25] with modification. All required reagents 
were warmed to 37 °C. Fifty microliters of sodium citrate-
anticoagulated plasma was then added into 100 μl of PT 
reagent (Thromboplastin-LI, Helena Laboratories, Beau-
mont, Texas, USA) at 37  °C, and the timer was started 
immediately to record the time to clot formation. Sam-
ples were tested in duplicate.
Statistics
Data analysis and graphs were generated using GraphPad 
Prism 6 and Microsoft Excel. Results are expressed as 
mean (±standard error of the mean). Groups were com-
pared using the non-parametric Kruskal–Wallis test. Sig-
nificance was defined as p < 0.05.
Results and discussion
Aldara was applied to C57Bl/6 WT mice in an area that 
approximated the surface area of involved dorsal skin 
on the K5-IL-17C mice (Fig. 1a) and involved skin from 
both models developed similar increases in acanthosis 
(epidermal thickness), an often-used surrogate measure 
of inflammation for murine skin, compared to control 
cream-treated and littermate controls (Fig.  1b, bottom 
row compared to top row). We and others have previ-
ously reported the increased presence of skin-infiltrating 
T cells, myeloid cells, and concomitant increases in pro-
inflammatory cell-derived cytokines, including elevated 
TNF-α, IL-12, IL-23, IL-17A and IL-17C in post-Aldara 
treated animals and in the chronic K5-IL-17C psoriasi-
form mouse model [13, 19, 20]. Thus, Aldara, or chronic 
stimulation of keratinocytes by increased levels of IL-17C 
leads to cutaneous infiltration of pro-inflammatory cells.
To determine whether the chronicity of skin-spe-
cific inflammation affects thrombotic clotting times, 
we performed the Rose Bengal photochemical carotid 
artery injury model on the acute inflammatory Aldara-
induced model (and control cream-treated mice) as 
well as the chronic K5-IL-17C mice (and their litter-
mate controls). C57Bl/6 WT mice treated topically with 
Aldara for 5  days had clotting times similar to C57Bl/6 
WT mice treated with control cream (Fig.  1c, trian-
gles vs. circles; 32.2 ± 3.0 vs. 31.4 ± 2.5 min, p = 0.97; 
n  =  25, n  =  21, respectively). In contrast, K5-IL-17C 
mice had significantly reduced times to form occlusive 
thrombi (enhanced thrombosis) compared to littermate 
controls (Fig.  1c, diamonds vs. squares; 15.7  ±  2.1 vs. 
26.5 ± 3.4 min, p < 0.01; n = 14, n = 21, respectively).
To examine potential differences in carotid arteries 
post-thrombosis, we harvested, sectioned and stained 
with H&E, the right carotid artery with the thrombus, 
from representative mice in each experimental group 
(Fig. 1d). Diameter measurements of carotids did not dif-
fer significantly compared to controls in either the acute 
Aldara model (385 ± 17.2, Aldara-treated vs. 401 ± 18.1, 
control cream-treated; n  =  9, n  =  8, respectively) or 
the chronic IL-17C model (422  ±  23.5, K5-IL-17C vs. 
404 ± 30.6, littermate controls; n = 4, n = 7, respectively) 
and despite K5-IL-17C mice having the largest carotid 
artery diameters, they also exhibited the shortest time to 
occlusive thrombus formation.
To further examine why chronic, and not acute skin 
inflammation promoted thrombosis, we examined plasma 
from representative mice to examine ex  vivo clotting 
times and lipid levels. No differences in prothrombin time 
(PT), an outcome measure that provides insight into influ-
ences on the extrinsic coagulation cascade pathway, were 
observed between Aldara-treated (17.4 ±  1.18  s; n =  7) 
and control cream-treated mice (15.6 ± 0.94 s; n = 6) and 
between K5-IL-17C mice (12.8 ± 0.69 s; n = 6) and their 
littermate controls (13.8 ± 0.17 s; n = 6). We also exam-
ined effects of both acute and chronic skin inflammation 
on the intrinsic pathway of the coagulation cascade, and 
measured activated partial thromboplastic time (aPTT). 
No differences were found between experimental groups 
or model systems (data not shown). Similarly, exami-
nation of plasma lipid levels also failed to demonstrate 
hyperlipidemia in either model system (data not shown).
These data demonstrate that chronic, but not acute, 
skin inflammation is associated with faster thrombus 
formation following activation using the Rose Bengal 
photochemical injury model of thrombosis and validate 
our prior observations describing shortened thrombo-
sis times in the KC-Tie2-psoriasiform model in a second 
skin-specific chronic inflammatory mouse model [17]. 
Others have recently reported increased endothelial dys-
function following chronic skin-specific overexpression 
of IL-17A (K14-IL-17A), including increased systolic 
blood pressure, left ventricular hypertrophy, and reduced 
survival compared with control animals [26]. Collectively, 
these findings suggest that chronicity and duration of 
skin-specific inflammation has the capacity to influence 
the systemic circulation, distant blood vessels, and pro-
mote thrombosis.
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These preclinical observations are consistent with 
clinical reports demonstrating that, (1) young psoria-
sis patients (with moderate-to-severe disease), develop 
chronic unrelenting systemic inflammation over a sus-
tained period of time and are at highest risk of devel-
oping CVD [27]; and (2) psoriasis patients with severe 
disease, and therefore more significant and prolonged 
systemic inflammation, have increased risk of thrombo-
embolism [28]. Interestingly, recent epidemiological data 
suggests that chronicity, or the length of time exposed 
to persistent inflammation, may play a role in longitudi-
nal increased risk of a myocardial infarction (MI) event, 
with the more severe psoriasis patients at the great-
est risk [29]. Psoriasis patients also had elevated levels 
of HsCRP (high-sensitivity C-reactive protein), a fre-
quently used measure of systemic inflammation and a 
surrogate predictor of CVD events [30]. Taken together, 
these results provide additional evidence that the length 
of time an individual is exposed to systemic inflamma-
tion, such as that derived from inflamed psoriasis skin, 
appears to increase the risk of developing CVD.
Increased risk of cardiovascular complications has 
been reported for patients with other chronic organ-
specific inflammatory diseases, including inflammatory 
bowel disease and rheumatoid arthritis, where risk of 
thromboembolism or levels of unstable carotid artery 
plaque are also significantly elevated (respectively) com-
pared to healthy controls; during a flare in either disease, 
this risk further increases [31, 32], and then decreases 
during disease remission [32]. Whether similar increases 
occur in psoriasis patients during acute flare remains to 
be examined.
Fig. 1 Chronic, but not acute, skin inflammation promotes shorter arterial clotting times in the Rose Bengal thrombosis assay. a Representative 
photographs of a C57Bl/6 WT mouse treated for 5 days with topical Aldara (left panel) and a K5-IL-17C mouse (right panel). b Representative images 
of H&E stained mouse back skin from a C57Bl/6 WT mouse treated for 5 days with topical Aldara and a K5-IL-17C mouse demonstrate increases in 
acanthosis compared to controls. c C57Bl/6 WT + Aldara clotting times (n = 25) are not different than C57Bl/6 WT + control cream (n = 21); how-
ever K5-IL-17C mice (n = 14) have significantly decreased clotting times compared to controls (n = 21), p < 0.01. d Representative photographs of 
cross sections of carotid arteries post-thrombus formation demonstrate no difference in diameter between the groups. Scale bar in b = 100 μm
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Inflammation and thrombosis are intertwined in vas-
cular pathology. Observations from pre-clinical and 
clinical studies indicate that inflammation can beget local 
thrombosis, and thrombosis can amplify inflammation 
([33] and references therein). For example, inflammatory 
mediators upregulate macrophage tissue factor expres-
sion within atherosclerotic plaques, and at the same 
time, platelets as mediators of thrombosis are critical 
for the recruitment of inflammatory cells to the vessel 
wall. Thus, accumulating data linking inflammation and 
thrombosis support the hypothesis that anti-inflamma-
tory therapies may limit thrombosis and that antithrom-
botic therapies may reduce vascular inflammation. It is in 
this context that one must view the contribution of skin-
specific inflammation to future adverse cardiovascular 
events.
Importantly, retrospective meta-analyses suggest some 
decrease in the incidence of myocardial infarctions in 
psoriasis patients treated with either TNF inhibitors or 
anti-IL-12/23 antibody, suggesting that aggressively tar-
geting chronic inflammation and its cellular drivers may 
reduce life-threatening co-morbidities associated with 
psoriasis [33, 34]. Our prior findings using the KC-Tie2 
mouse model support this, such that reversal of the skin 
disease, following gene repression, returned thrombosis 
times to control mouse levels; and reversed aortic root 
inflammation [17]. Similar improvements in vascular 
outcomes, including reduced oxidative stress in the heart 
and blood and attenuation of endothelial dysfunction 
were reported following TNF-α and IL-6 neutralization 
in the K14-IL-17A transgenic model [26]. Support for 
these preclinical findings are now being observed in pro-
spective studies, such that psoriasis patients treated with 
systemic biologic anti-inflammatory agents show a lower 
association with CVD events (cardiovascular death, myo-
cardial infarction, stroke) compared to patients treated 
with other anti-psoriatic therapies [35].
While there was a significant difference in time to 
occlusive thrombus formation between the acute and 
chronic models, we observed no difference in PT, aPTT, 
or lipid profiles, indicating a potential role for an immune 
cell mediator in the chronic disease model. Previously, 
we demonstrated that splenic and SDLN directly cor-
relate with, and reflect, circulating pro-inflammatory 
CD11b+Ly6Chigh monocytes in the chronic, skin-spe-
cific KC-Tie2 model [17]. Furthermore, we reported 
that these cells are increased in KC-Tie2 mice in the 
presence of enhanced thrombosis [17] and we recently 
validated the elevated presence of the human homolog 
(CD14+CD16++ intermediate monocytes) in psoriasis 
patient blood [18]. Finally, increased levels of circulat-
ing monocytes have been previously categorized as a 
risk factor for coronary heart disease [36], indicating that 
monocytes may participate in the cardiovascular out-
comes of the chronic disease model.
To determine if the observed increase in frequency 
of pro-inflammatory CD11b+Ly6Chigh monocytes may 
contribute to the promotion of thrombosis, we isolated 
skin-draining axial and inguinal lymph node (SDLN) cells 
from a subset of acute Aldara-treated C57Bl/6 WT mice, 
chronic K5-IL-17C animals, and their relative controls. 
Using flow cytometry, we measured CD11b, Ly6G, and 
Ly6C on the surface of SDLN cells (representative image 
in Additional file  1: Figure S1E, red box). Interestingly, 
CD11b+Ly6Chigh pro-inflammatory monocytes were sig-
nificantly increased in both the acute (Aldara-treated) and 
chronic (K5-IL-17C) skin inflammation models compared 
to their respective controls in both the SDLN (Fig.  2a; 
66.6  ±  4.4, Aldara-treated vs. 17.4  ±  2.6, control-cream 
treated; p = 0.02, n = 4, n = 4; and 74.2 ± 1.2, K5-IL-17C 
vs. 21.6 ± 2.8, littermate controls; p = 0.02, n = 3, n = 6; 
respectively) and spleen (Fig. 2b; 81.7 ± 1.2, Aldara-treated 
vs. 40.9  ±  4.8, control-cream treated; p  <  0.01, n  =  5, 
n = 5; and 73.9 ± 8.7, K5-IL-17C vs. 21.2 ± 1.3 littermate 
controls; p < 0.01, n = 4, n = 9; respectively). These data 
suggest that CD11b+Ly6Chigh monocytes accumulate rap-
idly in draining SDLN and spleen following skin inflam-
mation in both the acute and chronic models. Despite the 
increase in spleen- and SDLN-CD11b+Ly6Chigh cells, time 
to occlusive thrombosis formation failed to change signifi-
cantly between Aldara-treated and their respective control 
mice (Fig. 1c), suggesting that acute monocytosis alone is 
not prothrombotic.
In other chronic illnesses, such as HIV, increased lev-
els of circulating lymphocytes and leukocytes have also 
been observed and proposed to be responsible for the 
increased risk of cardiovascular events [37]. However, 
more important than numerical increases, perhaps, is 
the functional activation of these monocytes and lym-
phocytes, as suggested by Funderberg et  al. [38], who 
demonstrate that monocytes can become activated by 
exposure to oxidized LDL (oxLDL), leading to increased 
cardiovascular risk. Interestingly, psoriasis patients are 
dyslipidemic and have increased circulating and plaque 
oxLDL [39]. Moreover, stimulation of macrophages 
with psoriasis patient-isolated LDL increases produc-
tion of IL-6 and TNF-α, and also results in increased 
monocyte adhesion to human umbilical vein endothelial 
cells [40]. Thus, increases in oxLDL found in psoriasis 
patients and oxLDL-mediated effects on lymphocytes 
may provide further support for how skin-inflammation 
promotes distant vessel inflammation and atherothrom-
bosis. In the acute Aldara and chronic K5-IL-17C model 
systems, mice did not develop hyperlipidemia (data not 
shown), consistent with prior observations in KC-Tie2 
mice [17], suggesting that the promotion of thrombosis 
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occurs independent of lipid-mediated effects on lym-
phocytes in these model systems.
Other chronic inflammatory diseases have associated 
increased cardiovascular risk, and chronic inflammation 
can extend to inflamed vessels (arteries) that are likely 
to signal for additional pro-inflammatory leukocytes 
and lymphocytes [41], leading to increased infiltration 
of pro-inflammatory cells. This contextual activation of 
Fig. 2 CD11b+Ly6Chigh monocytes increase in both Aldara-treated and K5-IL-17C mice whereas CD11b+Ly6G+ neutrophils increase only in 
K5-IL-17C mice. a Representative flow cytometry dot plots of CD11b and Ly6C surface staining in skin-draining axillary and inguinal lymph nodes 
(LN). C57Bl/6 WT mice treated for 5 days with topical Aldara (n = 4 pooled samples) and K5-IL-17C mice (n = 3 pooled samples) have increases in 
skin-draining LN-CD11b+Ly6Chigh cells compared to their respective controls (n = 4 and n = 6 pooled samples; p = 0.02 and p = 0.02, respectively). 
Each point represents lymph nodes pooled from 2 to 3 animals. b Increased splenic-CD11b+Ly6Chigh are also observed in Aldara-treated WT mice 
(n = 5) and K5-IL-17C mice (n = 4) when compared to their respective controls (n = 5, n = 9; p < 0.01 and p < 0.01, respectively). Each point repre-
sents a single animal. c Aldara-treated mice have similar levels of SDLN-derived neutrophils (CD11b+Ly6G+) as control-cream treated mice (n = 4, 
n = 4) whereas SDLN CD11b+Ly6G+ cells are significantly increased in K5-IL-17C mice compared to littermate controls (n = 3 pooled samples, 
n = 6 pooled samples; p = 0.02, respectively). d Aldara-treated mice have similar levels of splenic CD11b+Ly6G+ cells as control-cream treated mice 
(n = 5, n = 5) and K5-IL-17C mice have significant increases in splenic CD11b+Ly6G+ cells compared to littermate controls (n = 4, n = 9 pooled 
samples; p < 0.01, respectively)
Page 8 of 10Golden et al. J Transl Med  (2015) 13:382 
both monocytic and endothelial cells may be dependent 
on the length of exposure to chronic inflammation; such 
that increased exposure, like that induced in the chronic 
K5-IL-17C model, but not acute exposure, similar to that 
elicited by Aldara application, are necessary to compro-
mise endothelial-monocyte (dys)function. Supporting 
this concept are reports that recent-onset plaque psoria-
sis patients fail to present with endothelial dysfunction 
[42] whereas established-plaque psoriasis patients do 
[43], consistent with the idea that disease duration may 
lead to the observed dysfunction in chronic patients. 
Additional observations in an additional preclinical 
model of psoriasiform skin involvement also demon-
strate that overexpression of IL-17A leads to systemic 
endothelial dysfunction, suggesting that chronic skin 
inflammation may result in vascular changes indicative 
of predisposition to eventual cardiovascular dysfunction.
Along with endothelial dysfunction, psoriasis patients 
also have increases in circulating endothelial cells and 
microparticles (MPs), which may promote coronary 
artery disease, acute coronary syndromes and athero-
thrombosis [44, 45]. Importantly, these decrease follow-
ing treatment with anti-TNF-α therapy [44] and could 
provide mechanistic insight into why TNF-α inhibition 
reduces risk of MI in psoriasis patients [46].
In addition to MPs and endothelial cells, other cellular 
mediators of thrombosis such as neutrophils have been 
previously reported to be elevated in preclinical psoria-
sis models [26] and human psoriasis patients [47]. There-
fore, we also examined CD11b+Ly6G+ neutrophils in 
both spleens and lymph nodes of the chronic and acute 
psoriasiform models. In the acute Aldara-treated mice, 
no increases in either SDLN or splenic resident neutro-
phils were observed compared to control-cream treated 
mice (Fig.  2c; SDLN: 1.90  ±  1.10, Aldara-treated vs. 
0.10 ± 0.06, littermate controls, p = 0.37, n = 4, n = 4; 
respectively; Fig. 2d. Spleen: 3.26 ± 0.17, Aldara-treated 
vs. 2.25  ±  1.62, littermate controls; p  =  0.28, n  =  5, 
n  =  4; respectively). In contrast, K5-IL-17C mice, had 
elevated neutrophil percentages when compared to lit-
termate controls in both the SDLN (Fig. 2c; 14.0 ± 1.87, 
K5-IL-17C vs. 1.21 ± 0.65, littermate controls, p = 0.02, 
n = 9, n = 4; respectively) and spleen (Fig. 2d; 47.6 ± 9.0, 
K5-IL-17C vs. 4.23 ± 0.66, littermate controls; p < 0.01, 
n = 9, n = 4; respectively).
Elevated monocytes and neutrophils, the activation 
status of these recruited immune cells, or potentially the 
micro-milieu the monocytes and neutrophils encounter, 
may all contribute to the thrombotic potential of the mice. 
Depletion of neutrophils from an alternative chronic skin 
inflammation model [26] resulted in decreased reactive 
oxygen species in peripheral blood, although changes in 
endothelial dysfunction were not examined. Targeted 
experiments designed to eliminate monocyte egress from 
the bone marrow, thus depleting these cells from circula-
tion in psoriasiform mice (i.e., backcross CCR2−/− and/
or CCR5−/− mice with either KC-Tie2 or KC-IL-17C) 
should address the necessity and importance of monocy-
tosis for thrombosis alterations. In addition, alternative 
cellular mediators of inflammation, such as neutrophil 
extracellular traps (NETs) [48] may play additional, as yet 
unidentified roles, in the thrombotic process as suggested 
previously by other investigators, using the Rose Bengal 
model of thrombosis [49, 50]. Duration, or chronicity of 
the skin inflammation, appears to be more correlative 
with shortened thrombosis times rather than accumula-
tion of pro-inflammatory cellular mediators. However, the 
duration of the cutaneous cellular response and result-
ant prolonged exposure to immune cells and derived 
cytokines may also be a critical factor rather than the 
appearance of transient pro-inflammatory cells.
Conclusions
Acute, as well as chronic, skin-specific inflammation pro-
motes the circulation and infiltration of proinflammatory 
CD11b+Ly6Chigh monocytes into the skin, however, sig-
nificant changes in neutrophil percentages and occlusive 
distant vessel thrombosis (following induction by Rose 
Bengal) occurs only in animals with chronic skin-specific 
inflammation. Our results provide evidence in an inde-
pendent second genetic skin-contained mouse model 
that chronic cutaneous inflammation promotes faster 
thrombosis following Rose Bengal photoinjury; however 
our findings also suggest that despite similar levels of skin 
involvement (body surface area) in acute and chronic 
models, the length of exposure to skin-elicited inflam-
mation, and elevated cellular participants, such as neu-
trophils, appear critical to pathogenic outcomes. Further 
work delineating the cellular and molecular response to 
psoriasis that promotes inflammation and poor CVD out-
comes, at the pre-clinical and clinical levels, are needed to 
better understand the link between psoriasis and CVD.
Additional file
Additional file 1: Figure S1. Gating strategy to identify the 
CD11b+Ly6GnegLy6Chigh monocyte population and CD11b+Ly6G+ 
neutrophils. (A) FSC-A vs. SSC-A plot was used on all events to identify 
monocytes. (B) The monocytes were next analyzed for live/dead cell pop-
ulations based on 7-AAD cell exclusion. (C) From the live monocyte gate, 
cells were gated for singlet and doublet events, and the doublet events 
were excluded. (D) The singlet cells were selected for CD11b+Ly6Gneg 
cells (based on istoypes for CD11b and Ly6G). The black, dashed line 
indicates the gate used to collect CD11b+Ly6G+ neutrophils. (E) From 
CD11b+Ly6Gneg gate, Ly6C expression was plotted versus SSC-A, and cells 
that expressed high levels of Ly6C (based upon isotype) and low on SSC-A 
(i.e., non-granular) were considered CD11b+Ly6Chigh monocytes. Cells that 
expressed low levels of Ly6C (based upon isotype) and low on SSC-A (i.e., 
non-granular) and eosinophils (high on SSC-A) were excluded.
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